Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(R)-2HG competitively inhibited BCAT1, which is a cytosolic enzyme, with respect to 2OG over a physiologically-relevant range of 2OG concentrations”
From Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) · cites this paper as Koivunen et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“Though it is found at low levels in normal cells, D-2HG can accumulate to millimolar levels in cancer cells expressing mutant IDH. At these high concentrations, D-2HG can inhibit αKG-dependent dioxygenases, including enzymes involved in histone and DNA demethylation (Chowdhury et al., 2011; Janke et al., 2017; Koivunen et al., 2012; Xu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Koivunen et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cell”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradatio”
BackgroundIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373 · cited 1×
“Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlie”
MethodAbsolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli
Bennett, B. D., Kimball, E. H., Gao, M., Osterhout, R., Van Dien, S. J., & Rabinowitz, J. D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.186 · Cited by 1,830 · cited 1×
“Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m value”
BackgroundGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brai”
ResultThe oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Cited by
Items 401–500 of 752
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity
Cai, M., Zhao, J., Ding, Q., & Wei, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24454 · Cited by 38
“D-2-HG was reported to stimulate PHD activity as a co-substrate through enzyme-catalyzed oxidation to α -KG or non-enzymatic mechanisms, triggering HIF-1 α destabilization [83 – 85].”
BackgroundOncometabolites in cancer: from cancer cells to the tumor microenvironment
Chen, L., & Huang, M. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00096-7 · Cited by 33
“In contrast, R-2-HG diminishes HIF-1α level via stimulating EGLN/PHD hydroxylases activity [19].”
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer
Yang, J., Harris, A. L., & Davidoff, A. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010240 · Cited by 32
“, 2-hydroxyglutarate [24], succinate [25], and fumarate [26]).”
Oligodendroglioma: A Review of Management and Pathways
Zerdan, M. B., & Assi, H. I. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.722396 · Cited by 32
“IDH mutated enzymes can promote proliferation and colony formation through its end metabolite 2HG (Koivunen et al., 2012; Bittinger et al., 2013).”
BackgroundPheochromocytoma: Gasping for Air
Jochmanová, I., Zhuang, Z., & Pacák, K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0231-4 · Cited by 30
Ma, T. C., Langley, B. C., Ko, B., Wei, N., Gazaryan, I. G., Zareen, N., Yamashiro, D. J., Willis, D. E., & Ratan, R. R. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.08.016 · Cited by 30
Regulatory Roles of Metabolites in Cell Signaling Networks
Li, F., Xu, W., & Zhao, S. (2013) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2013.05.002 · Cited by 32
Epigenetic Modifiers in Normal and Malignant Hematopoiesis
Haladyna, J. N., Yamauchi, T., Neff, T., & Bernt, K. M. (2015) · Epigenomics · doi:10.2217/epi.14.88 · Cited by 31
Xing, Z., Zhang, H., She, D., Lin, Y., Zhou, X., Zeng, Z., & Cao, D. (2019) · Acta Radiologica · doi:10.1177/0284185119842288 · Cited by 30
“Recently, some reports have showed that IDH-m gliomas could suppress the expression of hypoxiainducible-factor 1-alpha (HIF1A), leading to downstream inhibition of vascularity and angiogenesis (25,26).”
BackgroundPan, B., Hsu, C.-C., Wu, H., Chen, Y.-R., Zhou, X., Wang, S., Li, C., & Lin, H.-K. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01167-1 · Cited by 35
“In addition, D-2HG, but not L-2HG, reduces HIF levels by stimulating HIF prolyl 4-hydroxylases (EGLN) activity, which enhances the proliferation and soft agar growth of human astrocytes [144].”
Chen, J., Yang, J., Sun, X., Wang, Z., Cheng, X., Lu, W., Cai, X., Hu, C., Shen, X., & Cao, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-16427-w · Cited by 31
Moure, C. J., Diplas, B. H., Chen, L. H., Yang, R. R., Pirozzi, C. J., Wang, Z., Spasojević, I., Waitkus, M. S., He, Y., & Yan, H. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0309 · Cited by 29
Self-citationReitman, Z. J., Sinenko, S. A., Spana, E. P., & Yan, H. (2014) · Blood · doi:10.1182/blood-2014-05-577940 · Cited by 30
Self-citationJarzabek, M. A., Murphy, V., Callanan, J. J., Gao, C., Zagożdżon, A., Shiels, L., Wang, J., Ligon, K. L., Rich, B. E., Dicker, P., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.529 · Cited by 29
“GBM neurosphere lines (BT224-luc2 and BT248-luc2) were derived from Brigham and Women’s Hospital patients undergoing surgery according to IRB-approved protocols as previously described (Mehta et al, 2011; Koivunen et al, 2012).”
MethodSelf-citationSuccessive distinct high‐grade gliomas in L‐2‐hydroxyglutaric aciduria
Patay, Z. J., Orr, B. A., Shulkin, B. L., Hwang, S. N., Yuan, Y., Broniscer, A., Boop, F. A., & Ellison, D. W. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9782-8 · Cited by 29
“…studies have also shown that D-2-hydroxyglutarate promotes proliferation of human astrocytes through the stimulation of EGLN gene activity and a consequent reduction of hypoxia-inducible factor (HIF), a transcription factor that regulates cellular response to hypoxia) levels (Koivunen et al 2012).”
Law, J. M., Stark, S., Liu, K., Liang, N. E., Hussain, M. M., Leiendecker, M., Ito, D., Verho, O., Stern, A. M., Johnston, S. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00264 · Cited by 29
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
de la Fuente, M. I., Touat, M., van den Bent, M. J., Preusser, M., Peters, K. B., Young, R. J., Huang, R. Y., Ellingson, B. M., Capper, D., Phillips, J. J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae259 · Cited by 31
Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28
Kusi, M., Zand, M., Lin, L., Chen, M., Lopez, A., Lin, C.-L., Wang, C., Lucio, N. L. L., Kirma, N. B., Ruan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110220 · Cited by 30
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells
Gruber, E., So, J., Lewis, A. C., Franich, R. L., Cole, R., Martelotto, L. G., Rogers, A. J., Vidacs, E., Fraser, P., Stanley, K. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111182 · Cited by 29
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Pang, Y., Lu, T., Xu-Monette, Z. Y., & Young, K. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065493 · Cited by 31
Polívka, J., Pešta, M., Pitule, P., Hes, O., Holubec, L., Polívka, J., Kubíková, T., & Tonar, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24536 · Cited by 28
“2-HG, 2-hydroxyglutarate; CD, cluster of differentiation; EANO, European Association for NeuroOncology; FFPE, formalin-fixed, paraffin-embedded; FGF, fibroblast growth factor; GBM, glioblastoma multiforme; HGF, hepatocyte growth factor; HIF1α, hypoxia inducible factor 1 alpha; HIF2α, hypoxia inducible factor 2 alpha;…”
BackgroundInfluentialBlanc‐Durand, P., Gucht, A. V. D., Verger, A., Langen, K., Dunet, V., Bloch, J., Brouland, J., Lalonde, M. N., Schaefer, N. G., & Prior, J. O. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199379 · Cited by 30
Zhu, C., Chen, X., Liu, T., Cheng, L. L., Cheng, W., Cheng, P., & Wu, A. (2024) · Nature Communications · doi:10.1038/s41467-024-52888-0 · Cited by 32
“In addition, 2-HG may cause the degradation of HIF1 α through stimulating Prolyl-hydroxylase domain (PHD) activity 31 .”
Branched-chain α-ketoacids aerobically activate HIF1α signalling in vascular cells
Xiao, W., Shrimali, N. M., Vigder, N., Oldham, W. M., Clish, C. B., He, H., Wong, S. J., Wertheim, B. M., Arons, E., Haigis, M. C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01150-4 · Cited by 28
“The two enantiomers of 2HG (L2HG versus D2HG) had opposite effects on PHD activity with L2HG being an inhibitor and D2HG being an agonist 26 .”
Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics
Lee, S. C. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0449-ra · Cited by 27
Self-citationEnasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2
Dutta, R., Zhang, T. Y., Köhnke, T., Thomas, D., Linde, M. H., Gars, E. J., Stafford, M., Kaur, S., Nakauchi, Y., Yin, R. R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133344 · Cited by 29
Liu, N., Xia, W.-Y., Liu, S., Chen, H., Sun, L., Liu, M., Li, L.-F., Lu, H., Fu, Y., Wang, P., et al. (2016) · Scientific Reports · doi:10.1038/srep20489 · Cited by 31
BOLD asynchrony elucidates tumor burden in IDH-mutated gliomas
Petridis, P. D., Horenstein, C. I., Pereira, B., Wu, P. B., Samanamud, J. L., Marie, T., Boyett, D. M., Sudhakar, T. D., Sheth, S. A., McKhann, G. M., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab154 · Cited by 26
Padinharayil, H., Rai, V., & George, A. (2023) · Cancers · doi:10.3390/cancers15041070 · Cited by 30
“G affects the α-ketoglutarate (α-KG)-based prolyl oxidase potential of PHD2 and PHD1, which Cancers 2023, 15, 1070 6 of 31 promotes metamorphosis through a process involving the stability or destabilization of hypoxia-inducible factor 1 alpha subunit (HIF1A) [30,31].”
BackgroundHu, H., Wang, Z., Liu, Y., Zhang, C., Li, M., Zhang, W., Wang, K., Cai, J., Cheng, W., Huang, H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.018 · Cited by 26
Garrett-Bakelman, F. E., & Melnick, A. M. (2016) · Epigenomics · doi:10.2217/epi-2016-0008 · Cited by 25
Seok, J., Yoon, S., Lee, S., Jung, J. H., & Lee, Y. M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4649 · Cited by 26
“However, d -2HG inhibits hypoxia-inducible factor (HIF) expression by promoting the activity of the HIF‑1 prolyl hydroxylases Egl nine homolog (EGLN)1 and EGLN2, suggesting that d -2HG has dual functions as an oncometabolite and tumor suppressor (29).”
Self-citationThe Association between Whole‐Brain MR Spectroscopy and IDH Mutation Status in Gliomas
Goryawala, M., Lavi, E. S., Nagornaya, N., Heros, D. O., Komotar, R. J., & Maudsley, A. A. (2019) · Journal of Neuroimaging · doi:10.1111/jon.12685 · Cited by 25
Crake, R., Burgess, E. R., Royds, J. A., Phillips, E., Vissers, M. C. M., & Dachs, G. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.619300 · Cited by 25
RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Zhu, S., Luo, Y., Li, K., Mei, C., Wang, Y., Jiang, L., Wang, W., Zhang, Q., Yang, W., Lang, W., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi1782 · Cited by 27
Zinn, P. O., Mahmood, Z., Elbanan, M., & Colen, R. R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000120 · Cited by 26
Chen, J., Liu, F., Li, H., Archacki, S. R., Gao, M., Liu, Y., Liao, S., Huang, M. N., Wang, J., Yu, S., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.08.011 · Cited by 25
5-Hydroxymethylcytosine: a Potential Therapeutic Target in Cancer
Rodger, E. J., Chatterjee, A., & Morison, I. M. (2014) · Epigenomics · doi:10.2217/epi.14.39 · Cited by 25
Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis
Langstein, J., Milsom, M. D., & Lipka, D. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.008 · Cited by 26
“Along these lines, increased degradation of Hif1α, which is required for HSC quiescence, has been observed in mutant IDH1/2 cells and likely results in enhanced proliferation of HSCs harboring IDH1/2 mutations [180, 181].”
BackgroundKim, D., Kim, S., Kim, S. H., Chang, J. H., & Yun, M. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002006 · Cited by 26
TET family proteins: new players in gliomas
Bian, E., Zong, G., Xie, Y., Meng, X., Huang, C., Li, J., & Zhao, B. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1328-7 · Cited by 24
“Depletion of TET2 in immortalized human astrocytes phenocopies the transforming effects of mutant IDH expression, but TET2 mutations have not been described in brain tumors [55].”
BackgroundExpanding the Reach of Cancer Metabolomics
Metallo, C. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0433 · Cited by 24
“On the other hand, the (S)-2-HG enantiomer is generated and consumed by distinct enzymes and exhibits different biologic effects compared with (R)-2-HG (22).”
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer
Brody, J. R., Yabar, C. S., Zarei, M., Bender, J., Matrisian, L. M., Rahib, L., Heartwell, C., Mason, K., Yeo, C. J., Peiper, S. C., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1210743 · Cited by 24
Dodo, M., Kitamura, H., Shima, H., Saigusa, D., Wati, S. M., Ota, N., Katsuoka, F., Chiba, H., Okae, H., Arima, T., et al. (2018) · The Journal of Biochemistry · doi:10.1093/jb/mvy108 · Cited by 24
Epigenetic regulation by endogenous metabolite pharmacology
Kulkarni, R. A., Montgomery, D. C., & Meier, J. L. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.002 · Cited by 25
Auezova, R., Ivanova, N. E., Akshulakov, S., Жетписбаев, Б. Б., Kozhakhmetova, A., Ryskeldiyev, N., Mustafin, K., Teltayev, D., & Auezova, L. (2019) · Cancer Management and Research · doi:10.2147/cmar.s195754 · Cited by 24
“On the other hand, when D-HG accumulates as a result of the IDH1-mt enzyme’s activity, it may function as an agonist of α-KG for PHDs, promoting HIF degradation and thus slowing the tumor growth.(11) HIF-1α is involved in the activation of tumor-associated inflammatory signaling.”
BackgroundKotredes, K. P., Razmpour, R., Lutton, E. M., Alfonso‐Prieto, M., Ramirez, S. H., & Gamero, A. M. (2019) · Oncotarget · doi:10.18632/oncotarget.26848 · Cited by 25
“IDH mutations and (R)-2-HG production are also known to antagonize prolyl-hydroxylases, which are regulators of HIF-1α [13, 17], promote cell growth [18], alter cell morphology [19], increase metastatic potential [19], and are associated with overall longer survival in glioma patients [4].”
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers
Leca, J., Fortin, J., & Mak, T. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.11.013 · Cited by 25
Guo, X., Zhang, M., Cao, M., Zhang, W., Kang, Z., Xu, P., Ma, C., & Gao, C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003897 · Cited by 23
IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy
Molenaar, R. J., & Wilmink, J. W. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211062499 · Cited by 23
In Vivo Modeling of Malignant Glioma
Kegelman, T. P., Hu, B., Emdad, L., Das, S. K., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00007-x · Cited by 28
The role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 24
Molecular, histopathological, and genomic variants of glioblastoma
Karsy, M. J., Huang, T., Kleinman, G., & Karpel‐Massler, G. (2014) · Frontiers in bioscience · doi:10.2741/4268 · Cited by 27
IDHmutations: new genetic signatures in cholangiocarcinoma and therapeutic implications
Borger, D. R., & Zhu, A. X. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.32 · Cited by 23
Enantioselective analysis of melagatran via an LSPR biosensor integrated with a microfluidic chip
Guo, L., Yin, Y., Huang, R. Y., Qiu, B., Lin, Z., Yang, H., Li, J., & Chen, G. (2012) · Lab on a Chip · doi:10.1039/c2lc40388a · Cited by 23
Korbecki, J., Kojder, K., Jeżewski, D., Simińska, D., Tarnowski, M., Kopytko, P., Safranow, K., Gutowska, I., Goschorska, M., Kolasa, A., et al. (2020) · Biomolecules · doi:10.3390/biom10050727 · Cited by 22
“In addition, 2-hydroxyglutarate inhibits the activity of prolyl hydroxylases, which are enzymes that are involved in hypoxia inducible factor α subunits (HIF-α) degradation [94].”
BackgroundLiu, X., Yamaguchi, K., Takane, K., Zhu, C., Hirata, M., Hikiba, Y., Maeda, S., Furukawa, Y., & Ikenoue, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257090 · Cited by 26
“Thus the mechanism(s) on how HIF1α was regulated in the context of IDH mutations remained controversial.”
BackgroundInfluentialGenomic, epigenomic and transcriptomic landscape of glioblastoma
Dakal, T. C., Kakde, G. S., & Maurya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01414-8 · Cited by 22
“Changes in chro - matin structure, especially in acetylation, DNA methylation, and histone methylation are promoted by HRE transcription leads to promotion of several cancer hallmarks such as the production of immunosuppressive myeloid-derived suppressive cells and immunosuppressive cytokines (Torrisi et al. 2023).”
McCarthy, N. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3248 · Cited by 22
Mitochondrial metabolic remodeling in response to genetic and environmental perturbations
Hollinshead, K. E. R., & Tennant, D. A. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1334 · Cited by 24
“Consistent with either mechanism, IDH mutant cells display decreased HIF activation compared with their wild-type counterparts.(109) Mutations in IDH1 and IDH2, in both glioma and AML, occur early in tumor development and are thought to be mutually exclusive,(52,113) suggesting that either isoform is sufficient to con…”
BackgroundAspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation
Huang, C., Iwagami, Y., Zou, J., Casulli, S., Lu, S., Nagaoka, K., Ji, C., Ogawa, K., Cao, K. Y., Gao, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.041 · Cited by 23
Green, H. L. H., & Brewer, A. C. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00848-y · Cited by 22
Genetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer
Piruat, J. I., & Millán‐Uclés, Á. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00200 · Cited by 23
“Quite the opposite, 2-HG is able to activate PHD2 by prior non-enzymatic oxidation to α-KG (83, 84).”
BackgroundEmerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma
Clark, P. M., Mai, W. X., Cloughesy, T. F., & Nathanson, D. A. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0613-6 · Cited by 23
IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis
Rosiak, K., Smolarz, M., Stec, W. J., Peciak, J., Grzela, D. P., Winiecka-Klimek, M., Stoczyńska-Fidelus, E., Krynska, B., Piaskowski, S., & Rieske, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154726 · Cited by 21
“The increased concentrations of 2HG induced via either IDH1/2 mutation or its direct addition to the cell culture were shown to increase the proliferation and growth of astrocytes in soft agar [24] as well as propagate accumulation of histone changes and induced Nestin expression [22].”
BackgroundYin, F. Q., Keller, J., Kraus, D. H., Mangus, H., Li, F., & Liu, G. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112916 · Cited by 21
Protein Tyrosine Phosphatase Receptor Type Z in Central Nervous System Disease
Nagai, K., Fujii, M., & Kitazume, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084414 · Cited by 25
“The IDH mutation is considered the driver and primary mutation in this group of diffuse gliomas, followed by other various mutations and chromosomal abnormalities [36,37].”
BackgroundIsocitrate dehydrogenase 1 and 2 mutations in gliomas
Houdova, M. M., Drábek, J., Koudeláková, V., Trojanec, R., Kalita, O., & Hajdúch, M. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23456 · Cited by 23
“However, 2HG does not inhibit all JmjC-domain histone demethylases (Koivunen et al., 2012), and its exact role has yet to be resolved.”
BackgroundInfluentialGlutamate dehydrogenase1 supports HIF‐1α stability to promote colorectal tumorigenesis under hypoxia
Hu, K., Ding, Y., Zhu, H., Jing, X., He, W., Yu, H. T., & Wang, X. (2023) · The EMBO Journal · doi:10.15252/embj.2022112675 · Cited by 21
“This result was supported by a previous report showing that the IDH1-R132H mutant utilized aKG as a substrate and produced R2HG, which did not stabilize HIF1a protein (Koivunen et al, 2012).”
ResultPediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies
Voon, H. P. J., Hii, L. L., Garvie, A., Udugama, M., Krug, B., Russo, C., Chüeh, A. C., Daly, R. J., Morey, A., Bell, T. D. M., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03122-5 · Cited by 20
“Human SU_ DIPG_4, SU_DIPG_33, SU_DIPG_36 [83] and ICR_B184_2D and BT237 anaplastic oligodendroglioma cells [69] were cultured in Neurobasal-A/DMEM/F12 media (Gibco Thermo Fisher, cat no. 10888–022 and 11,330–032) with NEAA, 2 mM Glu-tamax, penicillin/streptomycin, 10 mM HEPES, 1 mM sodium pyruvate,…”
MethodResultComplex role of HIF in cancer: the known, the unknown, and the unexpected
Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 24
“by increasing PHD1 and PHD2 activity to promote transformation of immortalized human astrocytes (Figure 3A).(129) This”
Wen, H., Cho, H. R., Yun, T., Kim, H., Park, C., Lee, S., Choi, S. H., & Park, S. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12950 · Cited by 20
“This change in metabolism and the increase in 2-HG level itself have been suggested at the core of the tumorigenesis mechanism of the mutations (Figueroa et al. 2010; Koivunen et al. 2012; Lu et al. 2012; Yang et al. 2012; Losman et al. 2013).”
BackgroundSelf-citationNassereddine, S., Lap, C. J. G., & Tabbara, I. A. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182443 · Cited by 21
“Stimulation of prolyl 4-hydroxylases results in aberrant HIF-1α signaling, which has been linked to cancer stem cell formation and chemo-resistance of leukemic blasts.(11,13) Variously, COX inhibition makes leukemic cells become dependent on anti-apoptotic BCL-2 for cell survival, which is induced as a direct response…”
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
Drummond, K. J., Spiteri, M., Cain, S. A., Jones, J., Shaya, S., Topp, M. D., Lu, T., Tobler, R., Valkovic, A., Moore, Z., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03884-4 · Cited by 20
“While the relationship with mIDH and HIF-1α expression has been contentious 34,35 , IFN has been shown to promote HIF-1α expression independent of mIDH (ref.”
IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells
Hu, X., Li, L., Eid, J. E., Liu, C., Yu, J., Yue, J., & Trent, J. C. (2022) · Disease Markers · doi:10.1155/2022/7729968 · Cited by 20
“Conversely, D-2HG was shown to act as an activator rather than an inhibitor of PHDs, ultimately leading to decreased levels of HIF-1α [20, 21].”
BackgroundThe Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 27
Genomic discoveries in adult astrocytoma
Wang, J., & Bettegowda, C. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.12.002 · Cited by 21
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells
Kim, G., Choi, S. Y., Oh, T.-I., Kan, S.-Y., Kang, H., Lee, S., Oh, T., Ko, H. M., & Lim, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112679 · Cited by 21
“Koivenen et al. have shown that increased R-2HG in IDH1R132H-overexpressing human astrocytes enhances cellular proliferation and anchorage-independent growth by the activation of Egl nine homolog (EGLN) and inactivation of hypoxia-inducible factor (HIF) [19].”
BackgroundInfluentialSelf-citationLi, Z., Zhen, S., Su, K., Tumber, A., Yu, Q., Dong, Y., McDonough, M. A., Schofield, C. J., & Zhang, X. (2020) · Chemical Communications · doi:10.1039/d0cc06353c · Cited by 19
Contralesional Structural Plasticity in Different Molecular Pathologic Subtypes of Insular Glioma
Huang, Z., Li, G., Li, Z., Sun, S., Zhang, Y., Hou, Z., & Xie, J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636573 · Cited by 19
“Excess α-HG inhibits α-KG-dependent enzymes and causes alterations in cellular metabolism, epigenetic regulation, redox state, and DNA repair, all of which contribute to carcinogenesis including acute myeloid leukemia (AML), chondrosarcoma, and glioma (38, 39).”
BackgroundEnglander, Z. K., Horenstein, C. I., Bowden, S. G., Chow, D. S., Otten, M. L., Lignelli, A., Bruce, J. N., Canoll, P., & Grinband, J. (2018) · Radiology · doi:10.1148/radiol.2017170790 · Cited by 20
Wang, Y., Liu, B., Li, F., Zhang, Y., Gao, X., Wang, Y., & Zhou, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274239 · Cited by 18
“In a study focusing on enantiomer-speci fi c mechanisms, it was found that IDH1/2 mutant variants can convert 2-oxoglutarate (2-OG) to (R)-2HG rather than (S)-2HG. (R)- 2HG can activate PHD activity, thereby reducing the stability and levels of HIFs (103).”
BackgroundDeciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer
Hao, J., Huang, Z., Zhang, S., Song, K., Wang, J., Gao, C., Fang, Z., & Zhang, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107437 · Cited by 18
Disruption of the HIF-1 pathway in individuals with Ollier disease and Maffucci syndrome
Poll, S. R., Martin, R. P., Wohler, E., Partan, E. S., Walek, E., Salman, S., Groepper, D., Kratz, L. E., Cernach, M. C. S. P., Jesús-García, R., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010504 · Cited by 19
Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Trovarelli, G., Sbaraglia, M., Angelini, A., Bellan, E., Pala, E., Belluzzi, E., Pozzuoli, A., Borga, C., Tos, A. P. D., & Ruggieri, P. (2024) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000002960 · Cited by 18
“Mutated IDH enzymes produce D-2-hydroxyglutarate oncometabolite [11], which accumulates in cells, leading to histone and DNA hypermethylation and impairing normal cell differentiation and promoting tumorigenesis [8, 26].”
BackgroundDas, B. R., Tangri, R., Ahmad, F., Roy, A., & Patole, K. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7261 · Cited by 18
“Asian Pacific Journal of Cancer Prevention, Vol 14, 2013 7264 2-hydroxyglutarate, a putative oncometabolite (Koivunen et al., 2012; Losman et al., 2013) and therefore IDH1 and IDH2 mutations are likely the integrally involved in the pathogenesis of malignant transformation (i.”
Oncometabolite Accumulation and Epithelial-to-Mesenchymal Transition: The Turn of Fumarate
Janin, M., & Esteller, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.020 · Cited by 20
“Nevertheless, variations have been found in the epigenetic modifications between accumulation of L and D isomers of 2HG (Koivunen et al., 2012).”
BackgroundLi, T., Cox, C. D., Ozer, B. H., Nguyen, N. T., Nguyen, H. N., Lai, T. J., Li, S., Liu, F., Kornblum, H. I., Liau, L. M., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0367 · Cited by 18
“Further adding complexity, D-2-HG does not mimic all IDH mutation effects (44), and accumulation of IDH1-generated D-2-HG is able to alter and/or dysregulate a variety of other pathways through D-2-HG–mediated inhibition of other dioxygenases, including histone lysine demethylases (45), regulators of the HIF pathway (…”
BackgroundLi, M., Li, G., Yu, B., Luo, Y., & Li, Q. (2019) · Shock · doi:10.1097/shk.0000000000001347 · Cited by 19
“Inactivating SDH causes the accumulation of succinate, which inhibits 2-oxoglutaratedependent enzymes that mark HIF-1a for polyubiquitylation and proteasomal degradation (10).”
BackgroundLvu, W., Xu, F., Chen, C., & Zhang, B. (2020) · Bioscience Reports · doi:10.1042/bsr20201037 · Cited by 19
“Its mutation is supposed to be an early event in glioma formation and can promote the proliferation and colony formation of normal human astrocyte cell normal human astrocyte cells [22].”
Hu, Y., Chen, Y., Wang, J., Kang, J. J., Shen, D. D., & Jia, Z. Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.593102 · Cited by 18
“Excessive 2-HG can activate prolyl hydroxylase (PHD) and then promote the degradation of hypoxia induced factor (HIF), which can weaken tumor microvascular proliferation (2, 3).”
BackgroundMethodNota, B., Hamilton, E. M. C., Sie, D., Öztürk, Ş., van Dooren, S. J. M., Ojeda, M. R. F., Jakobs, C., Christensen, E., Kirk, E. P., Sykut‐Cegielska, J., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101961 · Cited by 20
Spatial heterogeneity in glioblastoma: Decoding the role of perfusion
Saha, S., Bhat, A., Kukal, S., Phalak, M., & Kumar, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189383 · Cited by 19
The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase
Tinoco, G., Wilky, B. A., Paz-Mejia, A. C., Rosenberg, A. E., & Trent, J. C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e648 · Cited by 18
Bruce‐Brand, C., & Govender, D. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206813 · Cited by 18
Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening
Duan, Z., Liu, J., Niu, L., Wang, J., Feng, M., Chen, H., & Luo, C. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.040 · Cited by 17
Avliyakulov, N. K., Rajavel, K. S., Le, K., Guo, L., Mirsadraei, L., Yong, W. H., Liau, L. M., Li, S., Lai, A., Nghiemphu, P. L., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1371-z · Cited by 16
“Additionally, the IDH1 mutation may result in several cellular changes such as a hyper-methylated phenotype, a distinct gene expression profile, and modulation of dioxygenase activity [6, 13, 14].”
BackgroundAnother small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
Shim, E., & Sudarshan, S. (2015) · Oncoscience · doi:10.18632/oncoscience.165 · Cited by 17
“The L-enantiomer of 2HG (L-2HG) is generally more potent at inhibiting α-KG-dependent dioxygenases as demonstrated by cell-free and in vitro studies [6,7,9].”
BackgroundYang, J., Chen, X., Jin, S., & Ding, J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105491 · Cited by 16
“In recent years, 2-HG has emerged as an important metabolite associated with cell metabolism (16, 17), epigenetic regulation (18, 19), DNA repair (20 – 22), hypoxia signaling (23), and immune response (24 – 27).”
Background
Metadata
- Authors
- Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., Verhaak, R. G. W., Yan, H., & Kaelin Jr, W. G.
- Affiliations
- University of Oulu (FI)
- Brigham and Women's Hospital (US)
- Duke University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Calgary (CA)
- University of Utah (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 484-488
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656605
- OpenAlex
- W2142898716
- Cited by
- 727
- References
- 41
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 32 · 2022: 35 · 2021: 44 · 2020: 56 · 2019: 52 · 2018: 66 · 2017: 63 · 2016: 61 · 2015: 57 · 2014: 70 · 2013: 59 · 2012: 43
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA140316)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- R-enantiomer, IDH1 mutation, IDH2 mutation, hypoxia-inducible factor, glioma, astrocyte proliferation, oncometabolites, cancer metabolism, histone demethylation, DNA hypermethylation, CpG island methylator phenotype
- MeSH terms
- Astrocytes, Cell Line, Cell Transformation, Neoplastic, Enzyme Activation, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Nuclear Proteins, Oncogenes, Procollagen-Proline Dioxygenase, Cell Line, Tumor, Cell Proliferation, Dioxygenases, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.